FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

| Washington, | D.C. | 20549 |
|-------------|------|-------|

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL             |     |  |  |  |  |  |  |  |
|--------------------------|-----|--|--|--|--|--|--|--|
| OMB Number: 3235-0287    |     |  |  |  |  |  |  |  |
| Estimated average burden |     |  |  |  |  |  |  |  |
| hours per response:      | 0.5 |  |  |  |  |  |  |  |

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person*     Campbell Bradley L     |  |                         |                               |            |                        | 2. Issuer Name and Ticker or Trading Symbol AMICUS THERAPEUTICS, INC. [ FOLD ] |        |         |                              |                 |  |                 |                  |   | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)                         |                       |  |  |  |  |  |  |
|--|--|-------------------------|-------------------------------|------------|------------------------|--|--------|---------|------------------------------|-----------------|--|-----------------|------------------|---|---|-----------------------|--|--|--|--|--|--|
|  |  |                         |                               |            |                        |  |        |         |                              |                 |  |                 |                  |   | Director  |                       | 10% Owner  |  | vner                                   |  |  |  |
| (Last)   | (Fi  | irst)                   | (Middle)                      |            | 3. [                   | Date of Earliest Transaction (Month/Day/Year)                                  |        |         |                              |                 |  |                 |                  |   | Officer below)  | (give title           |  | Other (s                                 | specify                                |  |  |  |
| l ` ′  | `  |                         |                               |            |                        | 11/01/2021   |        |         |                              |                 |  |                 |                  | Chief Operating Officer                                     |   |                       |  |  |  |  |  |  |
| C/O AMICUS THERAPEUTICS, INC.                                    |  |                         |                               |            |                        |  |        |         |                              |                 |  |                 |                  |   |   | •                     |  |  |  |  |  |  |
| 3675 MARKET STREET   |  |                         |                               |            |                        |  |        |         |                              |                 |  |                 |                  |   |   |                       |  |  |  |  |  |  |
| (041)  |  |                         |                               |            | -   4. 1               | 4. If Amendment, Date of Original Filed (Month/Day/Year)                       |        |         |                              |                 |  |                 |                  | 6. Individual or Joint/Group Filing (Check Applicable Line) |   |                       |  |  |  |  |  |  |
| (Street)   | TI DIIIA D   | Δ.                      | 10104                         |            |                        |  |        |         |                              |                 |  |                 |                  | X Form filed by One Reporting Person                        |   |                       |  |  |  |  |  |  |
| PHILAD   | ELPHIA P.  | A                       | 19104                         |            |                        |  |        |         |                              |                 |  |                 |                  | Form filed by More than One Reporting                       |   |                       |  |  |  |  |  |  |
|  |  |                         |                               |            | -                      |  |        |         |                              |                 |  |                 |                  | Person  |   |                       |  |  |  |  |  |  |
| (City)   | (S   | tate)                   | (Zip)                         |            |                        |  |        |         |                              |                 |  |                 |                  |   |   |                       |  |  |  |  |  |  |
|  | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |                         |                               |            |                        |  |        |         |                              |                 |  |                 |                  |   |   |                       |  |  |  |  |  |  |
| 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Y |  |                         |                               |            |                        | Executi  |        |         |                              | ction<br>Instr. | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 and                            |                 |                  | Benefici  |   | es<br>ally            | Form<br>(D) or   | : Direct<br>r Indirect                   | 7. Nature<br>of Indirect<br>Beneficial |  |  |  |
|  |  |                         |                               |            |                        | (Month/Day/Year)   |        | 8)      |                              |                 |  |                 |                  |   | Owned Following Reported  |                       |  | Ownership<br>(Instr. 4)                  |  |  |  |  |
|  |  |                         |                               |            |                        |  |        |         |                              | v               | Amount   | (A) or<br>(D)   | Price            | Trar  |   | action(s)<br>3 and 4) |  |  | , ,                                    |  |  |  |
| Common Stock 11/01/202   |  |                         |                               |            | 2021                   | 21   |        |         | M                            |                 | 10,515   | A               | \$4.3            | 4.38 40   |   | 7,783                 |  | D  |  |  |  |  |
| Common Stock 11/01/202   |  |                         |                               |            | 2021                   |  |        |         | S <sup>(1)</sup>             |                 | 10,515   | D               | \$11.32          | 23(2)   | 457,268   |                       |  | D  |  |  |  |  |
|  |  | -                       | Гаble I                       | I - Deriva | ative                  | Secu   | ıritie | es Aco  | uired                        | l, Dis          | posed of,  | or Ber          | neficial         | ly O  | wned  |                       |  |  |  |  |  |  |
|  |  |                         |                               | (e.g.,     | puts,                  | calls  | , Wa   | arrants | s, opti                      | ions            | , convertil  | ble sec         | urities          |   |   |                       |  |  |  |  |  |  |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)              | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security            | (Month/Day/Year) if any | emed<br>on Date,<br>Day/Year) |            | ransaction ode (Instr. |  |        |         | e Exerc<br>ation D<br>h/Day/ |                 | 7. Title and Amour<br>of Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4) |                 | y D<br>Si<br>(li | Price of<br>erivative<br>ecurity<br>1str. 5)                | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4) | у                     | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | Beneficial<br>Ownership<br>tt (Instr. 4) |  |  |  |  |
|  |  |                         |                               |            |                        |  |        |         |                              |                 |  |                 | Amour            | it  |   |                       |  |  |  |  |  |  |
|  |  |                         |                               |            |                        |  |        |         | Date                         |                 | Expiration   |                 | Numbe            | r   |   |                       |  |  |  |  |  |  |
|  |  |                         |                               |            | Code                   | v  | (A)    | (D)     | Exerci                       | isable          | Date   | Title           | Shares           |   |   |                       |  |  |  |  |  |  |
| Stock<br>Options<br>(right to<br>buy)                            | \$4.38   | 11/01/2021              |                               |            | M                      |  |        | 10,515  | (3                           | 3)              | 06/04/2022   | Common<br>Stock | 10,51            | 5   | \$0.00  | 13,515                |  | D  |  |  |  |  |

## **Explanation of Responses:**

- 1. The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 2. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from \$10.50 to \$11.59. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. All of the options were fully vested and exercisable as of the transaction date.

## Remarks:

/s/ Christian Formica, Attorney-11/03/2021 in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.